The objective of the present study was to analyze in vivo the hypoglycemiant potential of the extracts from the root and leaf of the medicinal plant bardana, Arctium minus (Asteraceae). It was also carried out through pharmacognostics analysis of quality control. In the biological assays, 60 rats were induced to the experimental diabetes through endovenous injection of alloxan administration, in an only dose of 42 mg/kg. On the seventh day after the induction, the fast glycemia was dosed. The animals with glycemia superior to 190 mg/dL were redistributed in four groups to receive, for 21 days, some kind of treatment. Group 1: Glibenclamide in the dose of 0.071 mg/kg; Group 2: pure lyophilized extract of bardana root, 500 mg/kg; Group 3: pure lyophilized extract of bardana leaf, 200 mg/kg; and Group 4: physiological serum. After treatment, the pure extract of bardana root reduced in 34.6 ± 5.8% the glycemic levels, the pure extract of the leaf reduced in 22.9 ± 6.2% and the Glibenclamide 34.5 ± 6.2%. The placebo group kept the glicemy. This study suggests that the pure extract of Arctium minus, mainly the root extract, is able to reduce the plasmatic levels of glucose, with similar power to the synthetic medicine of Glibenclamide reference.
Arctium minus; Asteraceae; bardana; medicinal plant; hypoglicemiant effect
